Fortrea Holdings Inc. (FTRE) Stock Price & Analysis
Fortrea Holdings Inc. (FTRE) fell 3.62% to USD 17.06 as of September 9, 2026 at 12:30 UTC, according to Nexqual real-time market data.
FTRE last closed at USD 17.06; the session ranged USD 16.86–17.61 on volume of 1,519,512 shares. Market capitalization is —, with a 52-week range of USD 8.31–21.39 (NMS). Source: Nexqual, September 9, 2026 at 12:30 UTC.
Key Statistics (as of September 9, 2026 at 12:30 UTC)
| Price | USD 17.06 |
|---|---|
| Change | ▼ 3.62% (down) |
| Previous Close | USD 17.06 |
| Open | USD 17.06 |
| Day Range | USD 16.86 – 17.61 |
| 52-Week Range | USD 8.31 – 21.39 |
| Volume | 1,519,512 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (FTRE)
Nexqual's technical model rates FTRE "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of September 9, 2026 at 12:30 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 41.23 (neutral) |
| vs SMA50 | Below (USD 18.28) |
| MACD | -0.11 (negative) |
From Fortrea Holdings Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Intellectual Property In the course of conducting our business, we have developed, and continue to develop and use, proprietary software, systems, processes, databases and other intellectual property.
- We seek to protect our proprietary and confidential information and trade secrets through confidentiality agreements with employees, customers, and other third parties, as well as through administrative and technical safeguards.
- We believe our broad customer base positions us at the forefront of innovation in healthcare and allows us to help our customers efficiently bring the best therapeutic solutions to patients.
- Our integrated clinical pharmacology solution supports the increasing complexity in early phase trials with precision, quality and safety.
Partnerships
- On March 9, 2024, the Company, together with its wholly-owned subsidiary, Fortrea Inc., entered into an Asset Purchase Agreement (the "Purchase Agreement") with Endeavor Buyer LLC, an affiliate of Arsenal Capital Partners, to sell the operations of Fortrea Patient Access Inc. and its subsidiaries and Endpoint Clinical, Inc. and its subsidiaries; which are all collectively referred to as the Enabling Services Segment.
- The insights gathered show consistent alignment with industry benchmarks and demonstrate meaningful progress across key engagement drivers, including collaboration, inclusion, and confidence in leadership.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ELVN | Enliven Therapeutics, Inc. | USD 59.37 | ▼ 0.47% |
| VSTS | Vestis Corporation | USD 13.65 | ▲ 8.85% |
| CGON | CG Oncology, Inc. | USD 73.4 | ▼ 1.25% |
| APGE | Apogee Therapeutics, Inc. | USD 135.07 | ▲ 0% |
| EWTX | Edgewise Therapeutics, Inc. | USD 43.82 | ▲ 4.46% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:30 UTC. This page is informational and not investment advice.